This is a First-in-Human phase I study to evaluate the safety, tolerability and pharmacokinetic characteristics of MAX-40070 in Healthy SubjectThe study will be comprised of 2 parts; Part A and Part B. Part A will be conducted at NZCR, and Part B will be conducted at both NZCR and another site(s) in China (if required). Part A will include approximately 48 participants, and Part B will include approximately 30 participants.

Start Date28 Feb 2022

Sponsor / Collaborator

Maxinovel Pty., Ltd.

100 Clinical Results associated with MAX-40070

100 Translational Medicine associated with MAX-40070

100 Patents (Medical) associated with MAX-40070

Literatures (Medical) associated with MAX-40070

01 Nov 2024·Protein Science

Molecular and energetic analysis of the interaction and specificity of Maximin 3 with lipid membranes: In vitro and in silico assessments

Article

Author: Ruiz‐García, Jaime ; Escamilla‐Ruiz, Martha Itzel ; Hernández‐Adame, Pablo Luis ; Munoz‐Garay, Carlos ; Bertrand, Brandt

AbstractIn this study, the interaction of antimicrobial peptide Maximin 3 (Max3) with three different lipid bilayer models was investigated to gain insight into its mechanism of action and membrane specificity. Bilayer perturbation assays using liposome calcein leakage dose–response curves revealed that Max3 is a selective membrane‐active peptide. Dynamic light scattering recordings suggest that the peptide incorporates into the liposomal structure without producing a detergent effect. Langmuir monolayer compression assays confirmed the membrane inserting capacity of the peptide. Attenuated total reflection‐Fourier transform infrared spectroscopy showed that the fingerprint signals of lipid phospholipid hydrophilic head groups and hydrophobic acyl chains are altered due to Max3‐membrane interaction. On the other hand, all‐atom molecular dynamics simulations (MDS) of the initial interaction with the membrane surface corroborated peptide‐membrane selectivity. Peptide transmembrane MDS shed light on how the peptide differentially modifies lipid bilayer properties. Molecular mechanics Poisson–Boltzmann surface area calculations revealed a specific electrostatic interaction fingerprint of the peptide for each membrane model with which they were tested. The data generated from the in silico approach could account for some of the differences observed experimentally in the activity and selectivity of Max3.

100 Deals associated with MAX-40070

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Alopecia	Phase 1	NZ	Guangzhou Zaiji Medical Technology Co., Ltd.	31 Jan 2022
Dermatitis, Atopic	Phase 1	NZ	Guangzhou Zaiji Medical Technology Co., Ltd.	31 Jan 2022
Psoriasis	Phase 1	NZ	Guangzhou Zaiji Medical Technology Co., Ltd.	31 Jan 2022
Alopecia Areata	Discovery	-	Maxinovel Pty., Ltd.	28 Feb 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

MAX-40070

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation